As part of the guideline, in order to improve the robustness of the HercepTestTM scoring, it was suggested to change the requirements for HER2 IHC3+ from a > 10% strong complete membrane staining of the tumor cells to > 30%. This evidence concerns the gene ERBB2 and neoplasm.